SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma

The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC). Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.

Study Overview

• Status: Terminated
• Conditions: Carcinoma, Hepatocellular; Hepatoma
• Intervention / Treatment: Device: SIR-Spheres microspheres

Detailed Description

This study is a multi-institutional, non-randomized pilot study that aims to assess the safety and toxicity of hepatic arterial radioembolization using SIR-Spheres yttrium-90 microspheres (SIR-Spheres microspheres) in the treatment of patients with unresectable primary hepatocellular carcinoma (HCC). The study aims to recruit 40 patients over a period of 24 months.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Thomas Jefferson University - Kimmel Cancer Center
    • Pittsburgh, Pennsylvania, United States, 15213
      • UPMC Liver Cancer Center
  • Texas
    • Dallas, Texas, United States, 75203
      • The Liver Institute at Methodist Dallas
    • Houston, Texas, United States, 77030
      • MD Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• must have a confirmed diagnosis of HCC.
• at least 18 years of age.
• must have a confirmed diagnosis of HCC either by histological confirmation or, in a subject who exhibits a vascular liver mass in the presence of radiographically apparent cirrhosis, an alpha-fetoprotein (AFP) level greater than 500 International Units/milliliter (UI/ml).
• must present HCC that is not amenable to surgical resection or immediate liver transplantation, or that is not optimally treatable with local ablative techniques such as radio-frequency ablation due to its size, extent or presence of cirrhosis.
• must present measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as greater than or equal to 10 mm with spiral CT scan or greater than or equal to 20 mm using conventional techniques (CT, MRI).
• must present with a whole-liver tumor burden of greater than or equal to 15% and less than or equal to 70%
• must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
• must have normal organ and marrow function

Exclusion criteria:

Includes both the listed contraindications to SIR-Spheres® and the exclusion criteria specific to the setting of this investigational study:

• hepatic artery directed therapy within the previous 6 months.
• chemotherapy within the previous 4 weeks
• have not recovered from adverse events due to agents administered previously
• Prior external hepatic radiation therapy for HCC, more than two prior systemic chemotherapy regimes for HCC or any other concomitant therapy for HCC
• Currently receiving any other investigational agents for the treatment of their cancer.
• Any extra-hepatic metastases other than metastatic disease found in the lung, bone and/or abdominal lymph nodes that are not otherwise life limiting.
• Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least five years.
• Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.

• Any of the following contraindications to angiography and selective visceral catheterization:

  • Bleeding diathesis
  • Severe peripheral vascular disease
  • Portal hypertension with hepatofugal flow
• Female subjects who are pregnant or currently breastfeeding.
• Refusal or inability to use effective means of contraception in men or women of childbearing potential.
• Current enrollment in any other investigational drug or device study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: SIR-Spheres microspheres	Device: SIR-Spheres microspheres; SIR-Spheres Yttrium-90 microspheres

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Adverse Events Grade 3 or Higher	Using the National Cancer Institute Common Terminology Criteria (NCI-CTC) version 3.0 as recorded in the case report form.	From date of enrollment until the date of death from any cause assessed up 24 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Disease Progression	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.
Tumor Response Rate	Tumour response rates estimated by the proportion of patients with a best response of CR, PR or SD by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) with corresponding exact 90% confidence limits being reported. Per RECIST v1.0 for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.
Change From Baseline in Health-related Quality of Life		52 weeks
Overall Survival	Overall Survival is defined as the time interval between the date of enrollment and the date of death from any cause.	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.

Collaborators and Investigators

• Sponsor: Sirtex Medical
• Investigators: Principal Investigator: Ravi Murthy, MD, M.D. Anderson Cancer Center; Principal Investigator: T. Clark Gamblin, MD, UPMC Liver Cancer Center

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 18, 2007
• Primary Completion (ACTUAL): March 9, 2010
• Study Completion (ACTUAL): March 9, 2010

Study Registration Dates

• First Submitted: July 18, 2007
• First Submitted That Met QC Criteria: July 18, 2007
• First Posted (ESTIMATE): July 19, 2007

Study Record Updates

• Last Update Posted (ACTUAL): December 10, 2020
• Last Update Submitted That Met QC Criteria: November 16, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Keywords: HCC; brachytherapy; liver cancer; unresectable hepatocellular carcinoma; SIR-Spheres; Selective Internal Radiation Therapy (SIRT); Y-90 Microspheres
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Carcinoma; Carcinoma, Hepatocellular
• Other Study ID Numbers: STX 0106

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Originally there was a plan to share the data with the Data Monitoring Committee, however the study was closed early due to lack of enrollment and the Data Monitoring Committee did not convene.